Balyasny Asset Management LLC Coherus Bio Sciences, Inc. Transaction History

Balyasny Asset Management LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.59 - $3.85 $179,749 - $435,242	-113,050 Reduced 64.42%	62,451 $207,000
Q3 2023 Nov 14, 2023	BUY	$3.74 - $5.45 $656,373 - $956,480	175,501 New	175,501 $656,000
Q1 2023 May 15, 2023	SELL	$5.89 - $10.52 $464,320 - $829,312	-78,832 Reduced 26.64%	217,045 $1.48 Million
Q4 2022 Feb 14, 2023	SELL	$5.69 - $10.07 $2.87 Million - $5.08 Million	-504,073 Reduced 63.01%	295,877 $2.34 Million
Q3 2022 Nov 14, 2022	SELL	$7.17 - $13.87 $1.99 Million - $3.86 Million	-278,159 Reduced 25.8%	799,950 $7.69 Million
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $6.32 Million - $14.3 Million	1,078,109 New	1,078,109 $7.81 Million
Q4 2019 Feb 14, 2020	SELL	$16.33 - $21.37 $172,510 - $225,752	-10,564 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$16.3 - $23.37 $3.53 Million - $5.06 Million	-216,635 Reduced 95.35%	10,564 $214,000
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $1.64 Million - $2.77 Million	-125,171 Reduced 35.52%	227,199 $5.02 Million
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $2.19 Million - $4.05 Million	261,269 Added 286.79%	352,370 $4.81 Million
Q4 2018 Feb 14, 2019	BUY	$8.65 - $16.28 $305,085 - $574,195	35,270 Added 63.17%	91,101 $824,000
Q3 2018 Nov 14, 2018	SELL	$14.45 - $20.25 $3.82 Million - $5.36 Million	-264,492 Reduced 82.57%	55,831 $921,000
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $3.13 Million - $5.33 Million	305,572 Added 2071.53%	320,323 $4.49 Million
Q1 2018 May 15, 2018	BUY	$9.1 - $13.7 $134,234 - $202,088	14,751 New	14,751 $163,000

130

67.8M

1.68M

91.8K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $83.2M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.